Cognetivity expands into North American healthcare market
Published on 02 September 2021
A pioneer in AI-led cognitive assessment has taken its first step into the US and Canadian healthcare markets, alongside the burgeoning new area of ketamine-enhanced medical care.
Cognetivity Neurosciences has partnered with KetamineOne Capital Ltd for its Integrated Cognitive Assessment (ICA) to be deployed in Ketamine One’s clinics across North America.
The companies have also agreed to collaborate on mental health assessments and plan on conducting clinical trials within the Ketamine One clinic network.